PMC:7170368 / 2348-2482 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"90","span":{"begin":2,"end":6},"obj":"Gene"},{"id":"91","span":{"begin":20,"end":24},"obj":"Gene"},{"id":"92","span":{"begin":25,"end":33},"obj":"Gene"},{"id":"93","span":{"begin":72,"end":75},"obj":"Gene"},{"id":"94","span":{"begin":76,"end":79},"obj":"Gene"},{"id":"95","span":{"begin":83,"end":87},"obj":"Gene"}],"attributes":[{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"Gene:185"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"Gene:59272"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Gene:284"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"Gene:1636"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"Gene:283"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Gene:185"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}

{"project":"MyTest","denotations":[{"id":"32228222-16007097-27780683","span":{"begin":54,"end":55},"obj":"16007097"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":7,"end":11},"obj":"Body_part"},{"id":"T9","span":{"begin":48,"end":52},"obj":"Body_part"},{"id":"T10","span":{"begin":88,"end":92},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma12520"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T20","span":{"begin":96,"end":97},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T28","span":{"begin":80,"end":82},"obj":"Chemical"}],"attributes":[{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}

{"project":"2_test","denotations":[{"id":"32228222-16007097-27780683","span":{"begin":54,"end":55},"obj":"16007097"}],"text":"I/AT1R axis and the ACE2/Ang (1–7)/Mas receptor axis [5]. Targeting the ACE/Ang II/AT1R axis is a novel therapeutic strategy for hyper"}